The stock of Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) is a huge mover today! About 1.34M shares traded hands or 27.62% up from the average. Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) has risen 77.36% since March 3, 2016 and is uptrending. It has outperformed by 69.01% the S&P500.
The move comes after 9 months negative chart setup for the $439.30 million company. It was reported on Oct, 6 by Barchart.com. We have $6.17 PT which if reached, will make NASDAQ:ARWR worth $52.72M less.
Analysts await Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) to report earnings on December, 12. They expect $-0.37 earnings per share, up 11.90% or $0.05 from last year’s $-0.42 per share. After $-0.32 actual earnings per share reported by Arrowhead Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 15.63% negative EPS growth.
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Ratings Coverage
Out of 3 analysts covering Arrowhead Research Corp (NASDAQ:ARWR), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Arrowhead Research Corp has been the topic of 4 analyst reports since August 5, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating given on Thursday, May 19 by Chardan Capital Markets. The firm has “Overweight” rating by Piper Jaffray given on Friday, September 25. The stock has “Hold” rating given by RBC Capital Markets on Wednesday, August 5. Cantor Fitzgerald initiated it with “Buy” rating and $15 target price in Friday, August 19 report.
According to Zacks Investment Research, “Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company which develops novel drugs to treat intractable diseases primarily in the United States. The company’s proprietary Dynamic Polyconjugate platform develops drugs based on the RNA interference mechanism which silences disease-causing genes. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA which are in different clinical trial phase. Arrowhead Pharmaceuticals, Inc., formerly known as Arrowhead Research Corporation, is headquartered in Pasadena, California.”
Insitutional Activity: The institutional sentiment decreased to 0 in Q2 2016. Its down 0.54, from 0.54 in 2016Q1. The ratio is negative, as 67 funds sold all Arrowhead Pharmaceuticals Inc shares owned while 0 reduced positions. 0 funds bought stakes while 0 increased positions. They now own 6,170 shares or 99.97% less from 18.16 million shares in 2016Q1.
The Manitoba – Canada-based Great West Life Assurance Can has invested 0% in Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR). Hanson Doremus Invest holds 470 shares or 0% of its portfolio.
Insider Transactions: Since August 22, 2016, the stock had 0 insider purchases, and 1 insider sale for $160,000 net activity. 20,000 shares with value of $160,000 were sold by Myszkowski Kenneth Allen on Monday, August 22.
Another recent and important Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) news was published by Schaeffersresearch.com which published an article titled: “Buzz Stocks: Transocean LTD, Arrowhead Pharmaceuticals Inc, and Intra-Cellular …” on September 29, 2016.
ARWR Company Profile
Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, incorporated on February 13, 2001, is a biopharmaceutical company. The Firm is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. RNAi is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. RNAi therapeutics leverage this natural pathway of gene silencing to target and shut down specific disease causing genes. The Company’s products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA. The Company’s ARC-520 is an RNAi therapeutic designed to treat chronic hepatitis B virus (HBV) infection by reducing the expression and release of new viral particles and viral proteins with the goal of achieving a functional cure for HBV. The Firm is conducting multiple Phase IIb clinical efficacy studies. The Company’s ARC-AAT is an unlocked nucleobase analog (UNA), which contains RNAi therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency (AATD), a rare genetic disease that can damage the liver and lungs of affected individuals. The Firm is conducting a Phase Ib clinical trial for ARC-AAT. The study is a multi-center, randomized, placebo-controlled, double blind, single dose-escalation, first-in-human study to evaluate the safety, tolerability and pharmacokinetics of ARC-AAT and the effect on circulating AAT levels.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.